Department OF Health Pharmaceutical Import Profile — Philippines (DGFT 2022–2026)

Name: Department OF Health Pharmaceutical Import Records from India — 5 Products, $1.9M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Department OF Health — Pharmaceutical Importer Profile (2026) | 5 Products, $1.9M Trade | TransData Nexus

Department OF Health

Pharmaceutical Importer · Philippines · Tuberculosis Medications Focus · $1.9M Total Trade · DGFT Verified

Department OF Health is a pharmaceutical importer based in Philippines with a total trade value of $1.9M across 5 products in 2 therapeutic categories. Based on 38 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Department OF Health sources from 19 verified Indian suppliers, with Macleods Pharmaceuticals Limited accounting for 25.8% of imports.

Department OF Health — Import Portfolio & Supplier Network

Department OF Health import network — 5 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Department OF Health?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Macleods Pharmaceuticals Limited	$1.7M	68	25.8%
Lupin Limited	$1.1M	25	17.3%
Mylan Laboratories Limited

What Formulations Does Department OF Health Import?

Formulation	Value	Ships
Levofloxacin 500MG tablets, net cont	$301.4K	13
[mixed vaccines for diphtheria and tetanus] diphtheria & tetanus vaccine (adult) 10 dose with vvm, vaccine for human	$294.2K	6
Ok pills-levonorgestrel 0.15MG and	$156.9K	4
Easy five tt vaccine dtwp-hep b-hib pentavalent vaccine (Each vial of 0.5 ML contains 1 dose) with vaccine vial	$150.0K	3
Dtp-hepb-hib (pentavalent vaccine) fullyliquid combination vaccine,single dosevial(0.5ML) vial,pediatric dose	$150.0K	3
Pretomanid 200MG tablets (26's) (21837 packs : 26's bottle)	$150.0K	3
Linezolid tablets 600 MG (10 x 10's x	$100.0K	2
Pyrazinamide tablet BP 500MG (24 x	$100.0K	2
Diphtheria and tetanus (dt)/ tetanus	$100.0K	2
Tb kit cat i & iii kit a (stop tb kit)	$100.0K	2
Rifampicin 150MG /isoniazid 75MG /	$100.0K	2
4 fdc 24x28t gdf rifampicin, isoniazid	$100.0K	2
Imipenem/cilastatin powder for	$100.0K	2
Rifa150+inh75+pzn400+etb275 24x28t gdf rifampicin,isoniazid,pyrazinamide and ethambutol hydrochloride tablet	$100.0K	2
Rifampicin 150MG+isoniazide 75MG+ pyrazinamide 400MG+ ethambutol 275MG hydrochloride tablets USP(7500 Box, size:24x28t)	$100.0K	2

Department OF Health imports 243 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 5 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Isoniazid	Tuberculosis Medications	$750.0K	15	0.0%	16
2	Pyrazinamide	Tuberculosis Medications	$350.0K	7	0.0%	8
3	Rifampicin	Advanced Antibiotics	$350.0K	7	0.0%	17
4	Ethambutol	Tuberculosis Medications	$250.0K	5	0.0%	12
5	Linezolid	Advanced Antibiotics	$200.0K	4	0.5%	8

Department OF Health imports 5 pharmaceutical products across 2 categories into Philippines totaling $1.9M.

Department OF Health — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

The Department of Health (DOH) in the Philippines is the principal government agency responsible for ensuring access to basic public health services, including the procurement and distribution of essential medicines. As a government procurement entity, the DOH plays a pivotal role in the pharmaceutical supply chain by sourcing medications to meet the healthcare needs of the Filipino population. Headquartered in Manila, the DOH operates under the jurisdiction of the Philippine government, with no parent company. Its mandate encompasses policy formulation, regulation, and direct procurement of pharmaceuticals, positioning it as a central figure in the nation's healthcare infrastructure.

2Distribution Network

The DOH's distribution network is extensive, encompassing regional and provincial health offices across the Philippines. While specific warehouse locations are not publicly detailed, the agency's logistics capabilities are designed to ensure equitable distribution of medical supplies nationwide. The DOH collaborates with various stakeholders, including local government units and private sector partners, to facilitate the efficient delivery of healthcare services. This collaborative approach enables the DOH to maintain a comprehensive geographic coverage, ensuring that essential medicines reach even the most remote areas of the country.

3Industry Role

In the Philippines' pharmaceutical supply chain, the DOH functions primarily as a government procurement entity. It is not a wholesaler, parallel importer, hospital supplier, or logistics intermediary. The agency's role is to source and procure essential medicines, which are then distributed through various channels to healthcare facilities and the public. This centralized procurement strategy aims to standardize the quality and pricing of pharmaceuticals, ensuring that all Filipinos have access to necessary medications.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Department OF Health

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

The DOH's sourcing strategy exhibits a high degree of concentration, with a portfolio comprising only five products across two therapeutic categories: Tuberculosis Medications (71.1%) and Advanced Antibiotics (28.9%). This focused approach suggests a strategic choice to concentrate on critical areas of public health, particularly in combating infectious diseases. The substantial import values—$750K for Isoniazid, $350K each for Pyrazinamide and Rifampicin, $250K for Ethambutol, and $200K for Linezolid—indicate a stable and ongoing relationship with Indian suppliers. The consistent importation of these specific formulations over multiple shipments reflects a stable and reliable supply chain, reducing the risk of supply disruptions.

2Supply Chain Resilience

The DOH's supply chain resilience is bolstered by its partnerships with multiple Indian pharmaceutical manufacturers, including MACLEODS PHARMACEUTICALS LIMITED, LUPIN LIMITED, and MYLAN LABORATORIES LIMITED. This diversification across 19 unique suppliers mitigates the risk associated with single-source dependency. The importation of 243 unique formulations further enhances supply chain flexibility, allowing the DOH to adapt to changing healthcare needs. While specific details on backup suppliers and shipping routes are not publicly disclosed, the agency's established relationships with reputable manufacturers and its adherence to regulatory compliance standards suggest a robust and resilient supply chain capable of maintaining the steady availability of essential medicines.

Importing Pharmaceuticals into Philippines — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Philippines

1Regulatory Authority & Framework

The Food and Drug Administration (FDA) of the Philippines is the primary regulatory body overseeing the importation and registration of pharmaceutical products. Key legislation governing pharma imports includes the Food, Drug, and Cosmetic Act (Republic Act No. 3720) and the FDA Act of 2009 (Republic Act No. 9711). These laws establish the FDA's authority to regulate all health products, including pharmaceuticals, ensuring their safety, efficacy, and quality. The marketing authorization pathway for Indian generics involves obtaining a Certificate of Product Registration (CPR) from the FDA, which requires compliance with local regulatory standards and may necessitate bioequivalence studies or the submission of a Certificate of Pharmaceutical Product (CPP) from the exporting country's regulatory authority.

2Import Licensing & GMP

Import licensing requirements in the Philippines mandate that pharmaceutical importers hold a valid License to Operate (LTO) issued by the FDA, specifying the "Drug Importer/Wholesaler" category. Additionally, each imported pharmaceutical product must have an FDA-issued Certificate of Product Registration (CPR). Good Manufacturing Practice (GMP) certificates from recognized authorities, such as the European Union (EU) GMP, World Health Organization (WHO) GMP, or Pharmaceutical Inspection Co-operation Scheme (PIC/S), are generally recognized by the FDA. Importers must also comply with the Bureau of Customs (BOC) regulations, including accreditation and proper documentation for each shipment.

Department OF Health — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

The DOH's focus on importing tuberculosis medications and advanced antibiotics aligns with the Philippines' public health priorities, addressing the high burden of infectious diseases in the country. The substantial import values for these products indicate a strategic emphasis on ensuring a steady supply of essential medicines to combat these health challenges. Market demand is driven by the prevalence of tuberculosis and the need for effective antibiotic treatments, necessitating reliable and affordable access to these medications.

2Sourcing Profile

The DOH's sourcing strategy is centered on procuring generic drugs, primarily from India, which is known for its robust pharmaceutical manufacturing sector. The agency's preference for finished pharmaceutical formulations, such as tablets, capsules, syrups, and injections, over raw active pharmaceutical ingredients (APIs) or bulk drugs, suggests a focus on ready-to-use products that meet the immediate needs of healthcare providers. India's established reputation for producing high-quality generics at competitive prices makes it a preferred sourcing partner for the DOH.

3Market Positioning

Seller's Guide — How to Become a Supplier to Department OF Health

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with the DOH, particularly if they can offer high-quality products that meet the agency's stringent regulatory requirements. Gaps in the DOH's current sourcing may exist in areas such as the supply of specialized formulations or the need for additional suppliers to ensure a more diversified supply chain. New entrants should focus on demonstrating product quality, reliability, and compliance with Philippine regulatory standards to gain the DOH's trust and business.

2Requirements & Qualifications

Indian exporters seeking to supply the DOH and the Philippine market must obtain a valid License to Operate (LTO) from the FDA, specifying the "Drug Importer/Wholesaler" category. Each pharmaceutical product must have an FDA-issued Certificate of Product Registration (CPR). Good Manufacturing Practice (GMP) certificates from recognized authorities, such as EU GMP, WHO GMP, or PIC/S, are generally recognized by the FDA. Compliance with labeling requirements, including English and Filipino language specifications, and adherence to batch testing and stability requirements are mandatory.

3How to Approach

Frequently Asked Questions — Department OF Health

What products does Department OF Health import from India?

Department OF Health imports 5 pharmaceutical products across 2 categories. Top imports: Isoniazid ($750.0K), Pyrazinamide ($350.0K), Rifampicin ($350.0K), Ethambutol ($250.0K), Linezolid ($200.0K).

Who supplies pharmaceuticals to Department OF Health from India?

Department OF Health sources from 19 verified Indian suppliers. The primary supplier is Macleods Pharmaceuticals Limited (25.8% of imports, $1.7M).

What is Department OF Health's total pharmaceutical import value?

Department OF Health's total pharmaceutical import value from India is $1.9M, based on 38 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Department OF Health focus on?

Department OF Health imports across 2 categories. The largest: Tuberculosis Medications (71.1%), Advanced Antibiotics (28.9%).

Get Full Department OF Health Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.